» Articles » PMID: 17465265

Prognostic Factors and Treatment-related Outcome in Patients with Uterine Papillary Serous Carcinoma

Overview
Journal Anticancer Res
Specialty Oncology
Date 2007 May 1
PMID 17465265
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: A retrospective analysis was performed in order to evaluate prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma (UPSC).

Patients And Methods: Between 1989 and 2003 forty-five patients with UPSC were treated at the McGill University Health Centre (MUHC), and therefore were included in the analysis. Age, race, history, tumor stage and grade, invasion and metastasis, treatment and outcome for each patient were evaluated.

Results: According to FIGO classification, Stage I, II, III, and IV tumors were identified in 36%, 9%, 44%, and 11% of the patients, respectively. At the time of analysis, 37.8% of patients (17/45) were dead due to disease, with a mean survival of 22 months (SD +/- 7.5 months). Cause-specific survival for the entire group was 69%, 66%, and 58% at 2, 3, and 5 years, respectively. With respect to disease stage, 5-year cause-specific survival for stage I, II, III, and IV was 100%, 75%, 43%, and 0%, respectively. Univariate analysis comparing cause-specific survival curves demonstrated a statistically significant difference for disease stage (p < 0.0001) and depth of myometrial invasion (p = 0.008). However, in multivariate analysis, only disease stage had a significant impact on cause-specific survival (p < 0.01).

Conclusion: Disease stage is the only independent significant prognostic factor regarding cause-specific survival in patients with UPSC.

Citing Articles

A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).

Chen L, Liu X, Li M, Wang S, Zhou H, Liu L Cancer Med. 2019; 9(3):988-998.

PMID: 31846222 PMC: 6997089. DOI: 10.1002/cam4.2648.


Review of Recommended Treatment of Uterine Carcinosarcoma.

Menczer J Curr Treat Options Oncol. 2015; 16(11):53.

PMID: 26374341 DOI: 10.1007/s11864-015-0370-4.


A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?.

Hou J, McAndrew T, Goldberg G, Whitney K, Shahabi S Reprod Sci. 2013; 21(4):532-7.

PMID: 24023030 PMC: 3960843. DOI: 10.1177/1933719113503414.


Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

Brinton L, Felix A, McMeekin D, Creasman W, Sherman M, Mutch D Gynecol Oncol. 2013; 129(2):277-84.

PMID: 23485770 PMC: 4006113. DOI: 10.1016/j.ygyno.2013.02.023.


Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.

Mhawech-Fauceglia P, Herrmann R, Kesterson J, Izevbaye I, Lele S, Odunsi K Eur J Surg Oncol. 2010; 36(12):1195-201.

PMID: 20926229 PMC: 5047383. DOI: 10.1016/j.ejso.2010.09.010.